Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Efficacy and safety of ofatumumab in real-world practice for MS: multi-centre study

Ana Paz Tamayo • 29 Jun 2026
EAN 2026
Multiple Sclerosis and Related Disorders Antibodies Ofatumumab

Ana Paz Tamayo, MD, University Hospital San Carlos, Madrid, Spain, discusses a multi-centre study exploring the efficacy and safety of ofatumumab in real-world practice for the treatment of multiple sclerosis (MS). The study found ofatumumab had encouraging efficacy outcomes and was well-tolerated, consistent with clinical trials. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

EU approval of tolebrutinib marks new era in progressive multiple sclerosis
1:27
EU approval of tolebrutinib marks new era in progressive multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Detecting and disrupting disability accumulation in MS: a session at EAN 2026
1:57
Detecting and disrupting disability accumulation in MS: a session at EAN 2026
Celia Oreja-Guevara • 29 Jun 2026
One big question with Celia Oreja-Guevara: what MS advance could transform care in the next 3 years?
0:43
One big question with Celia Oreja-Guevara: what MS advance could transform care in the next 3 years?
Celia Oreja-Guevara • 29 Jun 2026
A discussion at EAN 2026 on the impact of climate change on neurological diseases
13:26
A discussion at EAN 2026 on the impact of climate change on neurological diseases
Amalia Ghergu et al. • 28 Jun 2026
The content of VJNeurology is intended for healthcare professionals